Close
Help
Need Help?





JOURNAL

Breast Cancer: Basic and Clinical Research

512,503 Journal Article Views | Journal Analytics

Increased Circulating Level of the Survival Factor GP88 (Progranulin) in the Serum of Breast Cancer Patients When Compared to Healthy Subjects

Submit a Paper



Publication Date: 12 Jul 2011

Type: Original Research

Journal: Breast Cancer: Basic and Clinical Research

Citation: Breast Cancer: Basic and Clinical Research 2011:5 155-162

doi: 10.4137/BCBCR.S7224

Abstract

Introduction: GP88 (PC-Cell Derived Growth Factor, progranulin) is a glycoprotein overexpressed in breast tumors and involved in their proliferation and survival. Since GP88 is secreted, an exploratory study was established to compare serum GP88 level between breast cancer patients (BC) and healthy volunteers (HV). Methods: An IRB approved prospective study enrolled 189 stage 1–4 BC patients and 18 HV. GP88 serum concentration was determined by immunoassay. Results: Serum GP88 level was 28.7 + 5.8 ng/ml in HV and increased to 40.7 + 16.0 ng/ml (P = 0.007) for stage 1–3 and 45.3 + 23.3 ng/ml (P = 0.0007) for stage 4 BC patients. There was no correlation between the GP88 level and BC characteristics such as age, race, tumor grade, ER, PR and HER-2 expression. Conclusion: These data suggest that serial testing of serum GP88 levels may have value as a circulating biomarker for detection, monitoring and follow up of BC.


Downloads

PDF  (505.85 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)

XML

PMC HTML


Sharing




What Your Colleagues Say About Breast Cancer: Basic and Clinical Research
We are delighted about the speedy and professional process.
Dr Jan Endrikat (Saarland University Hospital, Germany)
More Testimonials

Quick Links




Follow Us We make it easy to find new research papers.
Email Alerts RSS Feeds
Facebook Google+ Twitter
Pinterest Tumblr YouTube




SUBJECT HUBS
Author Survey Results
author_survey_results
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.
See Our Results